Discounted Cash Flow Rating

Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Celcuity Inc. Common Stock (CELC)

Services-medical Laboratories

https://www.celcuity.com

Celcuity Inc is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications. The company's therapeutic candidate is gedatolisib, a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all Class I isoforms of PI3K and the mammalian target of rapamycin (mTOR).

16305 36TH AVENUE N, SUITE 100
MINNEAPOLIS, MN

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

09/20/2017

Market Cap

610,937,132

Shares Outstanding

24,200,000

Weighted SO

25,237,656

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

HOWL --.--%

EWTX --.--%

DBTX --.--%

CCCC --.--%

ANEB --.--%

ADAG --.--%

ACRV --.--%

ANAB --.--%

MLYS --.--%

Beta

0.8050

Last Div

0.0000

Range

8.389-22.188

Chg

0.7290

Avg Vol

372233

Mkt Cap

610937132

Exch

NASDAQ

Country

US

Phone

763 392 0767

DCF Diff

16.7115

DCF

-0.2865

Div Yield

0.0000

P/S

2660.3198

EV Multiple

-8.1125

P/FV

3.5900

Div Yield %

0.0000

P/E

-7.6802

PEG

20.5830

Payout

0.0000

Current Ratio

14.9490

Quick Ratio

14.9490

Cash Ratio

1.5597

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

18531.9679

CCC

-18531.9679

Gross Margin

0.4680

Op Margin

-371.8919

Pretax Margin

-359.6255

Net Margin

-359.6255

Eff Tax Rate

-0.0231

ROA

-0.2823

ROE

-0.6083

ROCE

-0.3128

NI/EBT

1.0000

EBT/EBIT

0.9670

EBIT/Rev

-371.8919

Debt Ratio

0.3294

D/E

0.5454

LT Debt/Cap

0.3525

Total Debt/Cap

0.3529

Int Coverage

-44.7258

CF/Debt

-0.6892

Equity Multi

1.6557

Rec Turnover

0.0000

Pay Turnover

0.0197

Inv Turnover

0.0000

FA Turnover

0.3742

Asset Turnover

0.0008

OCF/Share

-1.7276

FCF/Share

-1.7339

Cash/Share

7.3631

OCF/Sales

-289.2140

FCF/OCF

1.0036

CF Coverage

-0.6892

ST Coverage

-371.9051

CapEx Coverage

-277.0255

Div&CapEx Cov

-277.0255

P/BV

3.5900

P/B

3.5900

P/S

2660.3198

P/E

-7.6802

P/FCF

-9.1654

P/OCF

-9.5501

P/CF

-9.5501

PEG

20.5830

P/S

2660.3198

EV Multiple

-8.1125

P/FV

3.5900

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Dec 06, 08:30 Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium GlobeNewswire Inc. Dec 01, 11:02 Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium GlobeNewswire Inc. Nov 22, 08:05 Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference GlobeNewswire Inc. Nov 06, 07:30 Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call

Revenue Product Segmentation